Clinical Trials Logo

Polyneuropathies clinical trials

View clinical trials related to Polyneuropathies.

Filter by:
  • No longer available  
  • Page 1

NCT ID: NCT05014724 No longer available - Clinical trials for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

CIDP07 Rozanolixizumab Post Trial Access Program (the PTA)

Start date: n/a
Phase:
Study type: Expanded Access

This Post Trial Access (PTA) Program enables access to rozanolixizumab for eligible patients who have taken part in the CIDP04 trial (NCT04051944) and are continuing to derive benefit from treatment.

NCT ID: NCT04825626 No longer available - Clinical trials for Chronic Inflammatory Demyelinating Polyneuropathy

An Expanded Access IND for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Start date: n/a
Phase:
Study type: Expanded Access

This is an Individual Patient Expanded Access IND to evaluate the safety and preliminary efficacy of autologous HB-adMSCs for treating a single patient Chronic Inflammatory Demyelinating Polyneuropathy, CIDP. The expanded access program will include a screening period of up to 28 days, a 44-week treatment period, a safety follow-up at 50, and a 52-week end-of-study visit.

NCT ID: NCT04064983 No longer available - Polyneuropathies Clinical Trials

Individual Patient Expanded Access IND to Treat Polyneuropathy

Start date: n/a
Phase:
Study type: Expanded Access

This Individual Patient Expanded Access IND has been created as requested by an 58-year-old man who suffers from Polyneuropathy due to Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal gammopathy, and Skin abnormalities (POEMS) Syndrome. The patient will receive 8 infusions of 200 million cells every four weeks during a 28-week period to relieve the symptoms of Polyneuropathy arising due to POEMS.

NCT ID: NCT02939820 No longer available - Clinical trials for Amyloidosis, Hereditary

Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

Start date: n/a
Phase:
Study type: Expanded Access

The purpose of this study is to provide expanded access of patisiran to patients with hereditary transthyretin-mediated amyloidosis (hATTR).